Lataa...
New emerging targets in cancer immunotherapy: the role of TIM3
Currently, the programmed death-1/programmed death ligand-1 and the cytotoxic T-lymphocyte-associated protein 4 are the two commonly targeted immune-checkpoint inhibition pathways. These drugs have significantly improved the prognosis of many cancer types. While immune-checkpoint inhibitors have rev...
Tallennettuna:
| Julkaisussa: | ESMO Open |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6579568/ https://ncbi.nlm.nih.gov/pubmed/31275616 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000497 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|